MX2019007496A - Composiciones cannabinoides novedosas y metodos para tratar la epilepsia infantil. - Google Patents

Composiciones cannabinoides novedosas y metodos para tratar la epilepsia infantil.

Info

Publication number
MX2019007496A
MX2019007496A MX2019007496A MX2019007496A MX2019007496A MX 2019007496 A MX2019007496 A MX 2019007496A MX 2019007496 A MX2019007496 A MX 2019007496A MX 2019007496 A MX2019007496 A MX 2019007496A MX 2019007496 A MX2019007496 A MX 2019007496A
Authority
MX
Mexico
Prior art keywords
methods
childhood epilepsy
cannabinoid compositions
novel cannabinoid
treat childhood
Prior art date
Application number
MX2019007496A
Other languages
English (en)
Spanish (es)
Inventor
Jacobson Catherine
Joshua Eades Caleb
Original Assignee
Tilray Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tilray Inc filed Critical Tilray Inc
Publication of MX2019007496A publication Critical patent/MX2019007496A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pyrane Compounds (AREA)
MX2019007496A 2016-12-20 2017-12-20 Composiciones cannabinoides novedosas y metodos para tratar la epilepsia infantil. MX2019007496A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662436861P 2016-12-20 2016-12-20
PCT/IB2017/001683 WO2018115962A1 (en) 2016-12-20 2017-12-20 Novel cannabinoid compositions and methods of treating pediatric epilepsy

Publications (1)

Publication Number Publication Date
MX2019007496A true MX2019007496A (es) 2019-10-30

Family

ID=61028091

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019007496A MX2019007496A (es) 2016-12-20 2017-12-20 Composiciones cannabinoides novedosas y metodos para tratar la epilepsia infantil.

Country Status (12)

Country Link
US (1) US20200215022A1 (https=)
EP (1) EP3558297A1 (https=)
JP (2) JP2020514282A (https=)
KR (1) KR20190099221A (https=)
AU (1) AU2017381587A1 (https=)
BR (1) BR112019012776A2 (https=)
CA (1) CA3046320A1 (https=)
CL (1) CL2019001668A1 (https=)
CO (1) CO2019006911A2 (https=)
MX (1) MX2019007496A (https=)
PE (1) PE20200338A1 (https=)
WO (1) WO2018115962A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
IL261132A (en) * 2018-08-13 2018-11-04 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Formulated cannabis oil powder by nanoemulsifycation, methods of producing and uses thereof
GB2580653A (en) * 2019-01-21 2020-07-29 Gw Res Ltd Use of cannabinoids in the treatment of comorbidities associated with epilepsy
CA3130763A1 (en) 2019-02-25 2020-09-03 Ginkgo Bioworks, Inc. Biosynthesis of cannabinoids and cannabinoid precursors
US11759447B1 (en) 2019-06-26 2023-09-19 RCR BioPharma Compound and method for treating diseases and disorders
GB2598922A (en) 2020-09-18 2022-03-23 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
WO2022232574A1 (en) 2021-04-29 2022-11-03 Tilray, Inc. Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof
WO2023047308A1 (en) * 2021-09-22 2023-03-30 Avicanna Inc. Methods for reducing or eliminating incidence of seizures and sudden unexpected death in epilepsy
JP2025512495A (ja) 2022-04-12 2025-04-17 シャッケルフォード・ファーマ・インコーポレーテッド 発作性障害の治療

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1361864T3 (en) * 2001-02-14 2014-03-03 Gw Pharma Ltd FLYLDENDE SPRAY FORMULATIONS FOR buccal administration of cannabinoids
GB2530001B (en) * 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2531282A (en) * 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
MX385464B (es) * 2014-12-12 2025-03-18 Ojai Energetics Pbc Composiciones microencapsuladas de cannabinoides
HK1244715A1 (zh) * 2015-03-02 2018-08-17 阿福金制药有限责任公司 用大麻素的局部区域神经影响性疗法
EP3253375B1 (en) * 2016-02-11 2019-04-10 Gelpell AG Oral solid cannabinoid formulations, methods for producing and using thereof

Also Published As

Publication number Publication date
WO2018115962A1 (en) 2018-06-28
CO2019006911A2 (es) 2019-08-30
EP3558297A1 (en) 2019-10-30
PE20200338A1 (es) 2020-02-14
AU2017381587A1 (en) 2019-06-20
CL2019001668A1 (es) 2019-09-06
JP2020514282A (ja) 2020-05-21
JP2023001138A (ja) 2023-01-04
BR112019012776A2 (pt) 2019-12-10
CA3046320A1 (en) 2018-06-28
KR20190099221A (ko) 2019-08-26
US20200215022A1 (en) 2020-07-09

Similar Documents

Publication Publication Date Title
MX2019007496A (es) Composiciones cannabinoides novedosas y metodos para tratar la epilepsia infantil.
ZA201803366B (en) Antibody molecules to april and uses thereof
IL253727A0 (en) Pure cbd and cbda and methods, preparations and products using cbd or cbda
BR112017003414A2 (pt) composições compreendendo caseína e métodos para produzir as mesmas
MX2020002694A (es) Moleculas de anticuerpo que se unen a tim-3 y usos de las mismas.
PH12016501763A1 (en) Multispecific antibodies
JOP20150048B1 (ar) جزيئات جسم مضاد لـ lag-3 واستخداماتها
NZ720769A (en) Anti-siglec-8 antibodies and methods of use thereof
MX2021010460A (es) Metodo de tratamiento con tradipitant.
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
MX2016004802A (es) Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso.
MX386055B (es) Uso de medicamentos para disminuir la evolución de la enfermedad de parkinson.
BR112017010685A2 (pt) processo de fabricação de um polímero em multi-estágios, sua composição, seu uso e composição compreendendo o mesmo
PH12018501013A1 (en) Purified silicon, devices and systems for producing same
JP2017035918A5 (https=)
MY190543A (en) Silazane-siloxane random copolymers, their production and use
MX394471B (es) Composiciones y métodos para desgomar aceite.
UY37763A (es) 2,5-dibromopiridina y procesos para prepararla
PL123277U1 (pl) Szyna jezdna
BR112019000775A2 (pt) composições e métodos para marcar composições de hidrocarboneto com corantes não-mutagênicos
UA114708U (uk) Тяговий привід електробуса
TH150482S (th) หน้าตัดโลหะ
TH1601003165A (th) ลวดเหล็กกล้าสำหรับสลักเกลียว, สลักเกลียว เเละวิธีการสำหรับการผลิตสิ่งเดียวกันนั้น
TR201402557A2 (tr) Bcl-2 ekspresyonunu baskılayarak anti-kanser nitelik sergileyen bileşenler.
UA97535U (xx) Сорбційно-фільтруючий матеріал